Janssen to Present Key Data from Across Its Expansive Oncology Portfolio at ESMO 2020 Virtual Congress
(World News Cezch Republic)

FOR EMEA TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX OR UK Media Contacts: Alexandra Nisipeanu Mobile: +40 744 383 413 Email: adridean@its.jnj.com Noah Reymond Mobile: +31 621 385 718 Email: nreymond@its.jnj.com Investor Relations: Christopher DelOrefice Office: +1 732 524 2955 Jennifer McIntyre Office: +1 732 524 3922 Janssen to Present Key Data from Across Its Expansive Oncology Portfolio at ESMO 2020 Virtual Congress Safety and efficacy data from the Phase 1 CHRYSALIS study exploring amivantamab in combination with lazertinib in patients with advanced EGFR- mutated NSCLC Subgroup analysis of a Phase 2 study of erdafitinib in patients with metastatic or surgically...